Abstract: The invention relates to the use of the combination of n-lipoic acid and effectors of the glutathione metabolism for the treatment of disturbances of the cellular thiol status and accompanying disorders in kidney replacement therapy.

Abstract: The invention relates to a medicament containing an effector of the glutathione metabolism together with ?-lipoic acid for treating diabetes mellitus. This medicament enables disturbances of the thiol-disulfide status or those that occur, for example, in diabetes mellitus to be treated simultaneously, separately or in a temporally graduated manner.

Abstract: The present invention relates to the use of at least one effector of glutathione metabolism together with ?-lipoic acid, its salts and/or its pro-drugs for the simultaneous, separate or timed cytoprotective treatment of chronically obstructive lung diseases.

Abstract: The invention relates to a medicament containing an effector of the glutathione metabolism together with &agr;-lipoic acid for treating diabetes mellitus. This medicament enables disturbances of the thiol-disulfide status or those that occur, for example, in diabetes mellitus to be treated simultaneously, separately or in a temporally graduated manner.

Abstract: The invention relates to a medicament containing an effector of the glutathione metabolism together with &agr;-lipoic acid, its salts and/or prodrugs as a combined preparation for the simultaneous, separate or time-controlled treatment of a defective thiol-disulfide status in kidney replacement therapy and of clinical characteristics, which indicate a disorder of the thiol-disulfide status of immunocytes. The correction of a defective thiol metabolism is of fundamental importance as a basic therapy for treating a large number of diseases of different origin, in particular however in circumstances requiring an essential kidney replacement therapy.

Abstract: The invention relates to an agent for treating skin diseases and/or functional disorders of the skin on the basis of different medicaments and/or auxiliary substances through promotion of penetration from topical formulations into the skin. According to the invention, the agent is composed of a hyaluronate lyase produced by microbial means and a medicament, preferably a hydrophilic medicament and/or auxiliary substances in different galenic formulations including colloidal carrier systems. The areas of application for the invention in human and veterinary medicament relate to the treatment, prophylaxis and/or metaphylaxis of skin diseases, functional disorders of the skin, the processes of skin ageing and dry skin conditions.

Abstract: The invention relates to an agent for the treatment, prophylaxis and metaphylaxis of functional and structural disorders of the skin caused by external factors. The agent contains a hyaluronic acid partially digested with a microbiological hyaluronate lyase. The hyaluronic acid fragment mixture is incorporated in different galenic formulations to which other hydrophilic and/or lipophilic active substances and/or auxiliary substances can be added. Fields of application of the invention in human and veterinary medicine relate to the treatment and/or the prophylaxis of skin damage caused by environmental factors including UV, dry skin conditions and skin ageing.

Abstract: Lipid metabolic disorders, such as hyperlipidemia or hyperlipoproteinemia can be treated by administering to an afflicted individual an effective amount of 5-(1,2-dithiolan-3-yl) valeric acid (&agr;-lipoic acid) or one of its physiologically acceptable salts. Pharmaceutical compositions containing (&agr;-lipoic acid) and methods for making such compositions also are disclosed.

Abstract: The invention relates to a pharmaceutical preparation in a make-up which is suited for external application and which contains a dithranol derivative as an active ingredient.

Abstract: Lipid metabolic disorders, such as hyperlipidemia or hyperlipoproteinemia can be treated by administering to an afflicted individual an effective amount of 5-(1,2-dithiolan-3-yl) valeric acid (&agr;-lipoic acid) or one of its physiologically acceptable salts. Pharmaceutical compositions containing (&agr;-lipoic acid) and methods for making such compositions also are disclosed.